225Ac-TWS02

N/A

Report date: 2025/10/20 14:18:22
NME

Base Information

Drug Name225Ac-TWS02
Drug Alias NameN/A
ClassificationRadiation-emitting products > Nuclides > Actinium > 225AcRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Radionuclide Drug Conjugates
Mechanisms of ActionProstate-Specific Membrane Antigen binders
TargetsProstate-Specific Membrane Antigen
Therapy Area/IndicationsProstatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShandong UniversityThe Affiliated Huaian No.1 People'S Hospital Of Nanjing Medical University
China Registration ClassN/A

Develop Information

Active CompaniesThe Affiliated Huaian No.1 People'S Hospital Of Nanjing Medical University
Inactive CompaniesN/A
Active IndicationsProstatic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A